Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitroprusside vs Tirofiban for No-Reflow Prevention in Elective PCI (NOSLOWFLOW-II)
NCT03406832Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of sodium nitroprusside and tirofiban in ST-segment elevation myocardial infarction (STEMI) (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Coronary artery flow using thrombolysis in myocardial infarction (TIMI) flow grade, Coronary TIMI frame count and 1 more. Status: unknown.
02
Drugs
sodium nitroprussidetirofiban
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT03406832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406832.